Anacor Pharmaceuticals, Inc. Announces Development Agreement with Medicines for Malaria Venture (MMV) for the Treatment of Malaria

March 18, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has entered into a development agreement with Medicines for Malaria Venture (MMV) to develop Anacor’s compound AN3661 for the treatment of malaria.

Twitter
LinkedIn
Facebook
Email
Print

Alliances